LU91397I2 - "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard - Google Patents

"La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard

Info

Publication number
LU91397I2
LU91397I2 LU91397C LU91397C LU91397I2 LU 91397 I2 LU91397 I2 LU 91397I2 LU 91397 C LU91397 C LU 91397C LU 91397 C LU91397 C LU 91397C LU 91397 I2 LU91397 I2 LU 91397I2
Authority
LU
Luxembourg
Prior art keywords
recombinant
protein
silgard
gardasil
human papillomavirus
Prior art date
Application number
LU91397C
Other languages
English (en)
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25416951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91397(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of LU91397I2 publication Critical patent/LU91397I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91397C 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard LU91397I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90310992A 1992-06-25 1992-06-25
PCT/US1993/006109 WO1994000152A1 (fr) 1992-06-25 1993-06-24 Vaccin contre le papillomavirus

Publications (1)

Publication Number Publication Date
LU91397I2 true LU91397I2 (fr) 2008-02-14

Family

ID=25416951

Family Applications (8)

Application Number Title Priority Date Filing Date
LU91395C LU91395I2 (fr) 1992-06-25 2005-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix
LU91398C LU91398I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard
LU91396C LU91396I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
LU91393C LU91393I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix
LU91394C LU91394I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix
LU91399C LU91399I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard
LU91397C LU91397I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
LU91400C LU91400I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard

Family Applications Before (6)

Application Number Title Priority Date Filing Date
LU91395C LU91395I2 (fr) 1992-06-25 2005-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18"-Cervarix
LU91398C LU91398I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 11" Gardasil-Silgard
LU91396C LU91396I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
LU91393C LU91393I2 (fr) 1992-06-25 2007-12-14 "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" - Cervarix
LU91394C LU91394I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16"-Cervarix
LU91399C LU91399I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 16" Gardasil-Silgard

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU91400C LU91400I2 (fr) 1992-06-25 2007-12-14 "La protéine L1 recombinante du papillomavirus humain de type 18" Gardasil-Silgard

Country Status (12)

Country Link
US (2) US20020068326A1 (fr)
EP (2) EP1835029A1 (fr)
AT (1) ATE380871T1 (fr)
AU (1) AU697743C (fr)
DE (9) DE69334192T2 (fr)
DK (1) DK0647140T3 (fr)
ES (1) ES2294778T3 (fr)
FR (1) FR07C0073I2 (fr)
LU (8) LU91395I2 (fr)
NL (8) NL300316I1 (fr)
PT (1) PT647140E (fr)
WO (1) WO1994000152A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194839T3 (es) 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
RU2177999C2 (ru) * 1994-09-22 2002-01-10 Мерк Энд Ко., Инк. Экспрессирующий вектор (варианты)
DE122007000092I1 (de) 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
CA2295316C (fr) * 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6242176B1 (en) 1998-07-13 2001-06-05 Loyola University Of Chicago Papillomavirus cellular receptor
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
KR100629028B1 (ko) * 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002367977B2 (en) 2001-08-13 2008-06-19 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
US9623098B2 (en) 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
EP2414512A1 (fr) * 2009-04-03 2012-02-08 Deutsches Krebsforschungszentrum Augmentation de la production de particules analogues au papillomavirus avec un système d'expression de baculovirus modifié
CA2764374C (fr) 2009-06-05 2019-11-19 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
EP2556377B1 (fr) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
EP3587455A1 (fr) 2012-10-23 2020-01-01 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
JP7005504B2 (ja) 2016-02-22 2022-01-21 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 生体分子の固定化方法
WO2017200957A1 (fr) 2016-05-16 2017-11-23 Infectious Disease Research Institute Liposomes pégylés et procédés d'utilisation
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
WO2019051149A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
CA3141577A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
WO2022051022A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Arn co-lyophilisé et support lipidique nanostructuré
CA3266697A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) * 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US4596674A (en) * 1984-09-11 1986-06-24 Merck & Co., Inc. Immunogenic HAV peptides
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0320942A3 (fr) * 1987-12-18 1989-10-04 American Cyanamid Company Polysaccharides et composés macromoléculaires contenant ces polysaccharides
EP0451550A3 (en) * 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
ES2194839T3 (es) 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.

Also Published As

Publication number Publication date
US20020068326A1 (en) 2002-06-06
NL300322I1 (nl) 2008-03-03
FR07C0073I2 (fr) 2012-08-03
US8012679B1 (en) 2011-09-06
DE122007000100I1 (de) 2008-03-27
EP1835029A1 (fr) 2007-09-19
NL300319I1 (nl) 2008-03-03
DE122007000098I1 (de) 2008-03-27
LU91398I2 (fr) 2008-02-14
NL300318I2 (nl) 2008-03-03
PT647140E (pt) 2007-12-27
WO1994000152A1 (fr) 1994-01-06
DE69334192D1 (de) 2008-01-24
DE69334192T2 (de) 2008-12-04
AU697743B2 (en) 1998-10-15
DE122007000097I1 (de) 2008-03-27
NL300317I1 (nl) 2008-02-01
FR07C0073I1 (fr) 2008-01-02
DE122007000095I1 (de) 2008-03-27
DE122007000101I1 (de) 2008-03-27
LU91400I2 (fr) 2008-02-14
EP0647140B1 (fr) 2007-12-12
ATE380871T1 (de) 2007-12-15
LU91394I2 (fr) 2008-02-14
NL300318I1 (nl) 2008-02-01
AU1135295A (en) 1996-02-08
EP0647140A1 (fr) 1995-04-12
DK0647140T3 (da) 2008-02-04
DE122007000099I1 (de) 2008-03-27
DE122007000094I1 (de) 2008-03-27
EP0647140A4 (fr) 1997-03-19
NL300316I1 (nl) 2008-02-01
AU697743C (en) 2007-06-14
NL300320I1 (nl) 2008-03-03
LU91396I2 (fr) 2008-02-14
NL300315I1 (nl) 2008-02-01
DE122007000096I1 (de) 2008-03-27
LU91393I2 (fr) 2008-02-14
ES2294778T3 (es) 2008-04-01
LU91399I2 (fr) 2008-02-14
NL300315I2 (nl) 2008-03-03
NL300321I1 (nl) 2008-03-03
LU91395I2 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
LU91397I2 (fr) "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
DE122008000010I1 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine